Table 2.

Outcome measures during the ESRD Management Demonstration Project

DMO ADMO BDMO C
No significant survival advantage over FFS at 1 and 2 yearsSignificant survival advantage over FFS at 1 year and 2 yearsSignificant survival advantage over FFS at 1 year and 2 years
No significant difference in all-cause and cardiovascular hospitalizations compared with FFS at 1 and 2 yearsHospital admission and readmission rates were not significantly different from FFSSignificantly fewer SNF stays and physician visits than FFSSignificantly higher rates of transplant wait-listing compared with FFS, but no significant difference in transplantation percentages compared with FFSSignificantly lower percentage of cardiovascular hospitalizations but not all-cause hospitalization compared with FFS at 2 years (possibly an artifact of limited data)Hospital admission rates were not significantly different from FFS; readmission rates exceeded FFSSignificantly fewer physician visits than FFSNo significant difference in ED visits or SNF stays compared with FFS over 3-year evaluation periodTransplantation rates were significantly lower than FFS by year 2 and transplant wait-listing rates were significantly lower compared with FFSSignificantly lower percentage of all-cause and cardiovascular hospitalizations compared with FFS at 1 and 2 yearsNo significant difference in hospital admission and readmission rates compared with FFS over the 3-year evaluation periodSignificantly fewer SNF stays and physician visits than FFS; no significant difference in ED visitsTransplantation rates were significantly lower than FFS, and no significant difference seen in transplant wait-listing in the Demonstration Project compared with FFS
  • Service utilization analyses were conducted with multiple methods; only results consistent across all methods are highlighted here. DMO, disease management organization; FFS, fee-for-service; SNF, skilled nursing facility; ED, emergency department. Reprinted from reference 8.